The MarketWatch News Department was not involved in the creation of this content. Recognition follows Addyi's newly expanded FDA approval to treat both premenopausal and postmenopausal women under age ...

When it comes to a woman's health, Addyi is a vital medication. It can provide relief from the symptoms of female sexual dysfunction and help women to enjoy sex again. With the right insurance ...

Health officials have expanded access to a libido-boosting pill for women, approving its use beyond menopause. Flibanserin, sold as Addyi and first cleared by the U.S. Food and Drug Administration ...

Addyi is the first and only FDA-approved, hormone-free pill clinically proven to treat low sexual desire in women RALEIGH, N.C., July 24, 2025 /PRNewswire/ -- Sprout Pharmaceuticals today announced ...

Credit: Sprout Pharmaceuticals The approval was based on a randomized, double-blind, placebo-controlled phase 3 trial, which included 447 postmenopausal women with acquired, generalized HSDD.

For decades, postmenopausal women who raised concerns about low sexual desire were met with shrugs, platitudes or the familiar refrain that it was simply "normal" to lose interest with age. This week, ...

Addyi is now the #1 prescribed treatment* for frustrating low libido, women's most common sexual concern, and is backed by more than ten years of clinical and real-world patient data. TIME evaluated ...

On October 17, 2015, a new drug, Addyi (ADD-ee, flibanserin), becomes available to treat the 10 percent of women whose low libido, or “female hypoactive sexual desire disorder,” causes significant ...

RALEIGH, N.C., Jan. 29, 2026 /PRNewswire/ -- Sprout Pharmaceuticals today announced that Addyi® has been named "Best Prescription for Low Libido" in the 2026 Oprah Daily Menopause O-wards, one of the ...

Sprout joins the ranks of biotech's biggest names following record-setting growth, expanding prescriber adoption, and increasing payer coverage RALEIGH, N.C., April 29, 2026 /PRNewswire/ -- TIME has ...